Hlawaty, Hanna <br/><br/>
Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis.  [electronic resource] 

 -  Arteriosclerosis, thrombosis, and vascular biology  Apr 2009 
 - 518-24 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4636 
<br/><br/><label>Standard No.: </label>10.1161/ATVBAHA.108.181750  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Amidines--administration & dosage<br/>Angioplasty, Balloon--adverse effects<br/>Animals<br/>Carbamates--administration & dosage<br/>Carotid Artery, Common--drug effects<br/>Carotid Stenosis--etiology<br/>Cell Line<br/>Cell Movement--drug effects<br/>Cell Proliferation--drug effects<br/>Cholesterol, Dietary--administration & dosage<br/>Disease Models, Animal<br/>Extracellular Matrix--metabolism<br/>Humans<br/>Hyperplasia<br/>Leukotriene Antagonists--administration & dosage<br/>Leukotriene B4--metabolism<br/>Macrophages--drug effects<br/>Male<br/>Mammary Arteries--metabolism<br/>Matrix Metalloproteinase 2--metabolism<br/>Matrix Metalloproteinase 9--metabolism<br/>Muscle, Smooth, Vascular--drug effects<br/>Myocytes, Smooth Muscle--drug effects<br/>Organ Culture Techniques<br/>RNA Interference<br/>RNA, Small Interfering--metabolism<br/>Rabbits<br/>Secondary Prevention<br/>Stents<br/>Time Factors<br/>Transfection